Enzyvant and Altavant announce merger to accelerate rare disease ...
Dec 8, 2022 · Enzyvant Therapeutics (Enzyvant) and Altavant Sciences (Altavant) have announced a merger to form a biopharmaceutical company focused on accelerating the development of therapies for patients with rare diseases. The combined company, which retains the name Enzyvant, will have a full range of capabilities required to advance ‘bold science ...
PMLiVE | Pharmaceutical industry news, articles, jobs, reports, …
Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug. GSK expands immunology pipeline by acquiring Chimagen’s CMG1A46 in deal worth $850m. AbbVie to expand neuroscience pipeline with $1.4bn Aliada Therapeutics acquisition. Merck acquires oncology spinout Modifi Biosciences in deal worth $1.3bn.
Merck and Astellas/Pfizer’s bladder cancer combination receives …
Oct 11, 2024 · Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as a first-line combination treatment for advanced bladder cancer. The PD-1 inhibitor/antibody-drug conjugate combination ...
About T40 - PMLiVE
The aim of the T40 listing is to highlight those creative agencies having the most impact in the UK healthcare sector in 2023. The agencies were drawn from a shortlist based on selected 2023 healthcare awards schemes and specialist advertising, branding, creative and design agencies drawn from a number of sources including PMLiVE’s PMHub ...
Novartis restructures organisation to support growth and …
Apr 4, 2022 · Novartis has revealed its plans for the launch of a new organisational structure and operating model designed to support its innovation, growth, and product development goals as a focused medicines organisation over the next ten years. Key to the restructure is the integration of the pharmaceuticals and oncology business units, which will be ...
Top 40 overall - PMLiVE
21. Dice Medical Communications. 25-49 staff. 25-49 staff. Between 10 and 15 years. Dice is an independent communications agency that works with our clients to help launch, build, and continually develop great pharmaceutical brands. We …
Eli Lilly announces new $4.5bn US site for manufacturing and drug ...
Oct 3, 2024 · Eli Lilly has announced that it is investing $4.5bn into a new US facility for advanced manufacturing and drug development. The Lilly Medicine Foundry will give the company the ability to research new ways of producing medicines, while also scaling up manufacturing of medicines for clinical trials, Lilly said. The new centre will be located ...
Novo Nordisk acquires Embark Biotech in deal worth over €470m
Aug 31, 2023 · Novo Nordisk has announced its acquisition of Embark Biotech in a deal worth over €470m, marking another expansion of the Danish drugmaker’s cardiometabolic disease pipeline. The transaction gives the Danish drugmaker full rights to develop and commercialise Embark Biotech’s lead asset targeting obesity and other cardiometabolic diseases.
Novartis and GSK complete oncology and vaccines swap
Mar 2, 2015 · Under the terms of the deal GSK is paying $5.25bn in case for Novartis’ vaccines business while Novartis is stumping up $16bn for GSK’s oncology business. The two companies are also pooling their resources in consumer health, creating a joint venture that will be 63.5% owned by GSK. Details of the asset swap were first revealed last April.
UCLA launches study of personalised cancer vaccine in ... - PMLiVE
Aug 14, 2024 · UCLA launches study of personalised cancer vaccine in paediatric brain tumours. H3 G34-mutant diffuse hemispheric gliomas are brain tumours commonly found in adolescents and young adults. UCLA Health has announced the launch of a clinical trial to tackle aggressive brain tumours in adolescents and young adults using a personalised cancer vaccine.